


Immunogenicity Analysis of Anti-PD-1 Nivolumab (Opdivo) with and without Tregitopes



Predicted ADA: 2.91% ($\pm 5\%$)
 Observed ADA (Monotherapy): 11.18%
 Observed ADA (with Ipilimumab): 37.82%

Co-delivery with Ipilimumab resulted in higher ADA to Nivolumab

Nivolumab: 13.88 (Predicted ADA = 25-35%)

Nivolumab: -21.24 (Predicted ADA = 2.91%)

Proc Natl Acad Sci U S A. 2015 May 12; 112(19): 6140–6145.
 Published online 2015 Apr 27. doi: [10.1073/pnas.1417320112](https://doi.org/10.1073/pnas.1417320112)
 Immunology and Inflammation

PMCID: PMC4434760

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

[Emanuela Romano](#),^{a,b,c,1} [Monika Kusio-Kobialka](#),^b [Periklis G. Foukas](#),^{c,d} [Petra Baumgaertner](#),^c [Christiane Meyer](#),^c [Pierluigi Ballabeni](#),^e [Olivier Michielin](#),^{a,c} [Benjamin Weide](#),^f [Pedro Romero](#),^c and [Daniel E. Speiser](#)^c

[Author information](#) ▶ [Copyright and License information](#) ▶

Red: EpiMatrix Raw Score without Treg Epitopes
 Blue: Tregitope-adjusted EpiMatrix Score